Laboratory production of T cells-immune cells that grow naturally in the thymus gland-could provide new therapies against cancer, autoimmune disorders and organ transplant rejection. But they’re hard to grow in culture dishes; current methods yield too few cells of too little variety. Researchers from Massachusetts General Hospital in Boston and the Woburn, MA, biotechnology firm Cell Science Therapeutics have developed an artificial thymus that solves both problems. Constructed from a porous metal-and-carbon material typically used for bone repair and arranged in a three-dimensional matrix, the structure mimics the functions of a living-tissue thymus, generating a bumper crop of T cells that can adjust to new threats. Clinical trials start in 2002, with commercial availability expected a few years later. -M. Wortman
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.